Middle East and Africa Systemic Aspergillosis and Systemic Candidasis Market is expected to reach US$ 231.76 million by 2027

According to the latest study on ‘Middle East and Africa Systemic Aspergillosis and Systemic Candidasis Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Drug Class, Route of Administration, Distribution Channel, and Country,’ the Middle East and Africa Systemic Aspergillosis and Systemic Candidasis market was valued at US$ 184.03 million in 2019 and is projected to reach US$ 231.76 million by 2027; it is expected to grow at a CAGR of 3.0% during 2020–2027. The report highlights the trends prevailing in the Middle East and Africa systemic aspergillosis and systemic candidasis market and the factors driving the market along with those that act as deterrents to its growth.

Based on type, the systemic aspergillosis and systemic candidasis market is segmented voriconazole, liposomal, amphotericin B, systemic oral azoles, topical, antifungal agents, and others. In 2019, the systemic oral azoles segment accounted for the largest share of the Middle East and Africa systemic aspergillosis and systemic candidasis market. The growth of the segment attributes to the to rise in prevalence of fungal diseases is among the primary factors contributing to the dominance of the segment in the Middle East and Africa systemic aspergillosis and systemic candidasis market. Additionally, the outbreak of the COVID-19 pandemic has highly affected the countries in the Middle East and Africa region. Antifungal resistance occurs when fungi or fungus no longer respond to antifungal drugs. Only three types of antifungal drug species currently exist, so antifungal resistance can severely limit treatment options and can act negatively in systemic aspergillosis and systemic candidasis market. Systemic aspergillosis and systemic candidasis are the types of fungal infections. Molds cause aspergillosis infection and majorly affect the respiratory tract of an individual. Also, it is a severe pulmonary infection caused by Aspergillus, a common fungus that affects people with weakened immune systems or lung diseases. Moreover, severe fungal infections occur due to other health problems, including AIDS, asthma, cancer, organ transplantation, and corticosteroid therapies. Early accurate diagnosis allows prompt antifungal treatment; however, this is often delayed or unavailable, leading to death, severe chronic illness, or blindness. For instance, Candida Auris's emergence is considered one of the most severe problems associated with nosocomial transmission and infection control practices in the hospital environment.

Moreover, as per the study published by BioMed Central Ltd, it was revealed that among the 693 different bacterial and fungal bloodstream infections were identified throughout the study period. Among them, 248 cases of community-acquired, 371 cases of hospital-acquired, and 74 cases healthcare-associated. The overall risk of bloodstream infections was estimated to about 6.7 per 1000 admissions. Escherichia coli, Staphylococcus aureus, and Streptococcus pneumoniae were the most frequent causes of community acquired-bloodstream infections, and Klebsiella pneumoniae, Acinetobacter baumanii, and S.aureus were estimated for most commonly isolated in hospital-acquired bloodstream infections. Thus, the rising prevalence of acquired diseases is expected to drive the market.

Novartis AG, Sanofi, Pfizer Inc., Merck & Co., Inc., Bayer AG, Astellas Pharma Inc., GlaxoSmithKline plc., Abbott, Cipla Inc., Enzon Pharmaceuticals, Inc, are among the prominent players present in the systemic aspergillosis and systemic candidasis market. The market players are focused on mergers and acquisitions to sustain their position in the market. For instance, in April 2019 Cipla Technologies LLC and Pulmatrix, Inc. has entered into a Definitive Agreement for the co-development and commercialization of Pulmazole (PUR1900) – an inhaled iSPERSE formulation of the antifungal drug itraconazole for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma.

The report segments the Middle East and Africa systemic aspergillosis and systemic candidasis market as follows:

By Type

• Systemic Oral Azoles
• Voriconazole
• Liposomal Amphotericin B
• Topical Antifungal Agents
• Others

By Application

• Allergic Bronchopulmonary Aspergillosis (ABPA)
• Chronic Pulmonary Aspergillosis (CPA)
• Gastrointestinal Candidiasis
• Genitourinary Tract Candidiasis
• Others

By Country

• Germany
• UK
• France
• Italy
• Spain
• Rest of Europe